ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Trial Details

NCT ID

NCT06378138

Phase

PHASE2 / PHASE3

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• ICP-248
• Orelabrutinib

Locations (sample)

• Bengbu, Anhui, China|32.94083,117.36083
• Beijing, Beijing Municipality, China|39.9075,116.39723
• Chongqing, Chongqing Municipality, China|29.56026,106.55771
• Fuzhou, Fujian, China|26.06139,119.30611
• Lanzhou, Gansu, China|36.05701,103.83987

Key Eligibility Criteria

• Age ≥ 18 and ≤ 80 years.
• CLL/SLL is diagnosed by histopathology and/or flow cytometry according to the 2016 World Health Organization (WHO) classification criteria for lymp…
• Having an indication for treatment that meets the criteria for iwCLL 2018
• Subjects must have measurable lesion according to the Lugano 2014 Assessment Criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.